Imatinib is a tyrosine kinase inhibitor used in several malignancies, including chronic myeloid leukemia. Imatinib acts on multiple targets, including BCR-ABL, c-KIT, platelet-derived growth factor receptor, and colony-stimulating factor receptor-1.1 Multiple cutaneous adverse effects have been reported with administration including nonspecific rash, pruritus, hypopigmentation, and rarely, hyperpigmentation, particularly of the oral mucosa.1 We present a case of significant blue-gray hyperpigmentation of the face and trunk.
No takes yet. Share an insight, caveat, or question.
Garraway et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: